About Vallon

Advancing Novel Formulations to Reduce Medication Abuse

Company Overview

About Us

Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company’s lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection.

Leveraging the clinical success of dextroamphetamine, we are developing ADAIR through a streamlined 505(b)(2) U.S. FDA regulatory pathway, which is expected to obviate the need for large Phase 2 and Phase 3 efficacy and safety studies. If approved, ADAIR is expected to be the first abuse-deterrent, immediate-release formulation of dextroamphetamine.

Leadership

We are Driven by Accomplishment

Our leadership includes accomplished biopharmaceutical professionals who have developed and commercialized many of the best-known CNS products of the past two decades. Our team brings extensive experience operating across large pharma, specialty pharma, and start-up environments.

Key Accomplishments

  • 5 different billion-dollar products commercialized, including the two best-selling ADHD medications
  • 29 U.S. and international new products developed and/or approved, including 4 different ADHD drugs

Management Team

David Baker

President & CEO

Tim Whitaker, M.D.

Chief Medical Officer

Penny Toren

Senior VP, Regulatory Affairs & Project Management

Board of Directors

David Baker

President & CEO

Collaborations

We Collaborate with Industry Leaders

Developing products with disruptive potential requires collaboration. We are working with leading academics, businesses, professional organizations, and patient advocacy groups to advance our mission of bringing novel products to large markets in need.

Medice

Strategic Marketing Partner in EU

Lonza®

Formulation + Development

CHADD

Patient Advocacy

Abuse Deterrent Coalition

Patient Advocacy

APSARD

Industry Organization

BIO

Industry Organization

Life Sciences Pennsylvania

Industry Organization